Evaluating the clinical impact of a genomic classifier in prostate cancer using individualized decision analysis.

ABSTRACT:

Background

Currently there is controversy surrounding the optimal way to treat patients with prostate cancer in the post-prostatectomy setting. Adjuvant therapies carry possible benefits of improved curative results, but there is uncertainty in which patients should receive adjuvant therapy. There are concerns about giving toxicity to a whole population for the benefit of only a subset. We hypothesized that making post-prostatectomy treatment decisions using genomics-based risk prediction estimates would improve cancer and quality of life outcomes.

Methods

We developed a state-transition model to simulate outcomes over a 10 year horizon for a cohort of post-prostatectomy patients. Outcomes included cancer progression rates at 5 and 10 years, overall survival, and quality-adj

SUBMITTER: Lobo JM 

PROVIDER: S-EPMC4383561 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature